tal-t + serplulimab

TAL-T + serplulimab is an investigational **combination therapy** consisting of TAL-T (likely referring to **T cell antigen linker-T**, a specific cell therapy, though precise details about TAL-T are scarce) plus **serplulimab**, a monoclonal antibody checkpoint inhibitor targeting **Programmed cell death protein 1 (PD-1)**. Serplulimab (brand name Hetronifly) is a humanized IgG4 monoclonal antibody that blocks PD-1, thereby restoring anti-tumor T-cell responses that are inhibited by tumor cells expressing PD-L1 and PD-L2, and is approved for **extensive-stage small cell lung cancer (ES-SCLC)[2][4]**. The combination therapy aims to enhance immune-mediated tumor elimination via direct T cell engagement (TAL-T) and checkpoint inhibition (serplulimab), with trials exploring efficacy in small cell lung cancer and potentially transformed SCLC[1][2][5].

Brand names

Hetronifly

Other names

TAL-Tserplulimab